Delayed Follow-up Visits and Thyrotropin Among Patients With Levothyroxine During the COVID-19 Pandemic

• Published in: Journal of the Endocrine Society Vol. 6; no. 1; p. bvab181
• Main Authors: Inoue, Kosuke, Noh, Jaeduk Yoshimura, Yoshihara, Ai, Watanabe, Natsuko, Matsumoto, Masako, Fukushita, Miho, Suzuki, Nami, Hoshiyama, Ayako, Mitsumatsu, Takako, Suzuki, Ai, Kinoshita, Aya, Mikura, Kentaro, Yoshimura, Ran, Sugino, Kiminori, Ito, Koichi
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01-01-2022
• Subjects: Analysis; Care and treatment; Clinical; Epidemics; Japan; Medical research; Medicine, Experimental; Patient compliance; Thyroid diseases; Thyrotropin; Japan; COVID-19; TSH; levothyroxine; pandemic; delayed follow-up
• ISSN: 2472-1972; 2472-1972
• DOI: 10.1210/jendso/bvab181

Abstract
Context
The indirect effects of the COVID-19 pandemic on clinical practice have received great attention, but evidence regarding thyroid disease management is lacking.
Objective
We aimed to investigate the association between delayed follow-up visits during the pandemic and their serum thyrotropin (TSH) levels among patients being treated with levothyroxine.
Methods
This study included 25 361 patients who made a follow-up visit as scheduled (n = 9063) or a delayed follow-up visit (< 30 d, n = 10 909; ≥ 30 d, n = 5389) during the pandemic (after April 2020) in Japan. We employed modified Poisson models to estimate the adjusted risk ratio (aRR) of TSH greater than 4.5 mIU/L and greater than 10 mIU/L during the pandemic according to the 3 types of follow-up visit group (ie, as scheduled, delayed < 30 d, and delayed ≥ 30 d). The models included age, sex, city of residence, TSH levels, underlying thyroid disease, dose of levothyroxine, and duration of levothyroxine prescriptions.
Results
The mean age was 52.8 years and women were 88%. Patients who were older and had a higher dose or longer duration of levothyroxine prescriptions were more likely to make a delayed follow-up visit during the pandemic. Changes in TSH were larger among the delayed-visit groups than the scheduled-visit group. We found increased risks of elevated TSH levels during the pandemic among the delayed visit groups, particularly those with delayed visit of 30 or more days (TSH > 4.5 mIU/L, aRR [95% CI] = 1.72 [1.60-1.85]; and TSH > 10 mIU/L, aRR [95% CI] = 2.38 [2.16-2.62]).
Conclusion
A delayed follow-up visit during the COVID-19 pandemic was associated with less well-controlled TSH among patients with levothyroxine.